

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
03 March 2022 (03.03.2022)



(10) International Publication Number
WO 2022/043493 A1

(51) International Patent Classification:

C07K 14/55 (2006.01) C12N 15/09 (2006.01)
A61K 38/20 (2006.01) A61P 35/00 (2006.01)

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2021/073735

(22) International Filing Date:

27 August 2021 (27.08.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/071,627	28 August 2020 (28.08.2020)	US
20202306.5	16 October 2020 (16.10.2020)	EP
20216067.7	21 December 2020 (21.12.2020)	EP
21160466.5	03 March 2021 (03.03.2021)	EP
21162023.2	11 March 2021 (11.03.2021)	EP

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(71) Applicant: **ASCENDIS PHARMA ONCOLOGY DIVISION A/S** [DK/DK]; Tuborg Boulevard 12, 2900 Hellerup (DK).

(72) Inventors: **OKKELS, Sigurd**; c/o Ascendis Pharma A/S, Tuborg Boulevard 12, 2900 Hellerup (DK). **ROSEN, David B**; c/o Ascendis Pharma Inc., 500 Emerson Street, Palo Alto, California 94301 (US). **LAUFER, Burkhardt**; c/o Ascendis Pharma GmbH, Im Neuenheimer Feld 584, 69120 Heidelberg (DE). **KNAPPE, Thomas**; c/o Ascendis Pharma GmbH, Im Neuenheimer Feld 584, 69120 Heidelberg (DE).

(74) Agent: **BÜCHEL, Edwin**; Patentanwälte Isenbruck Bösl Hörschler PartG mbB, Seckenheimer Landstraße 4, 68163 Mannheim (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: GLYCOSYLATED IL-2 PROTEINS AND USES THEREOF

(57) Abstract: The present invention relates to an IL-2 protein sequence of the formula (Tag¹)_y - (Ala)_x - SEQ A - SEQ B - SEQ C - (Tag²)_z (I), wherein SEQ A has at least 89% sequence identity with SEQ ID NO:1; SEQ B has at least 76% sequence identity to SEQ ID NO:2 and comprises at least one glycosylation motif; SEQ C has at least 91% sequence identity with SEQ ID NO:4; Tag 1 and Tag² are independently a tag moiety; Ala is an alanine residue; x is 0 or 1; y is 0 or 1; and z is 0 or 1; to conjugates thereof and their uses in the treatment of cell-proliferation disorders.

WO 2022/043493 A1